A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
OBJECTIVE
To determine if progressive brain atrophy could be detected over 1- and 2-year intervals in relapsing MS, based on annual MR studies from the Multiple Sclerosis Collaborative Research Group (MSCRG) trial of interferon beta-1a (Avonex).


METHODS
All subjects had mild to moderate disability, with baseline expanded disability status scores ranging from 1.0 to 3.5, and at least two relapses in the 3 years before study entry. Atrophy measures included third and lateral ventricle width, brain width, and corpus callosum area.


RESULTS
Significant increases were detected in third ventricle width at year 2 and lateral ventricle width at 1 and 2 years. Significant decreases in corpus callosum area and brain width were also observed at 1 and 2 years. Multiple regression analyses suggested that the number of gadolinium-enhancing lesions at baseline was the single significant contributor to change in third ventricle width. Atrophy over 1 and 2 years as indicated by enlargement of the third and lateral ventricle and shrinkage of the corpus callosum was greater for patients entering the trial with enhancing lesions. Greater disability increments over 1 and 2 years were associated with more severe third ventricle enlargement.


CONCLUSIONS
In patients with relapsing MS and only mild to moderate disability, significant cerebral atrophy is already developing that can be measured over periods of only 1 to 2 years. The course of cerebral atrophy in MS appears to be influenced by prior inflammatory disease activity as indicated by the presence of enhancing lesions. Brain atrophy measures are important markers of MS disease progression because they likely reflect destructive and irreversible pathologic processes.
Department of Radiology-MRI, University of Colorado Health Sciences Center, Denver 80262, USA.
J H
JH
Simon
L D
LD
Jacobs
M K
MK
Campion
R A
RA
Rudick
D L
DL
Cookfair
R M
RM
Herndon
J R
JR
Richert
A M
AM
Salazar
J S
JS
Fischer
D E
DE
Goodkin
N
N
Simonian
M
M
Lajaunie
D E
DE
Miller
K
K
Wende
A
A
Martens-Davidson
R P
RP
Kinkel
F E
FE
Munschauer
C M
CM
Brownscheidle
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000328:Adult; D001284:Atrophy; D001921:Brain / Q000473:pathology*; D002552:Cerebral Ventricles / Q000473:pathology; D003337:Corpus Callosum / Q000473:pathology; D004185:Disability Evaluation; D018450:Disease Progression; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000473:pathology*; D012008:Recurrence; D012044:Regression Analysis
D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D000068556:Interferon beta-1a